Clinical Trial Update: 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety [Phase 3]

View source ↗

Summary

AstraZeneca-sponsored 48-week open-label Phase IIIb trial in dyslipidemia has completed, evaluating the efficacy and safety of the investigational treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Snippet

Sponsor: AstraZeneca | Conditions: Dyslipidaemia | Phase 3 | Status: COMPLETED